Hypogonadism, Male, Male Infertility
Conditions
Brief summary
The investigators shall study the effect of Sinopharm vaccination on semen parameters and serum testosterone
Detailed description
The investigators shall compare semen parameter (sperm density, sperm motility, and percentage of abnormal sperm form) as well as morning serum testosterone before vaccination, and 3 months after the second dose of the vaccine.
Interventions
DIAGNOSTIC_TESTSemen analysis
Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
Sponsors
Cairo University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Receiving Sinopharm COVID-19 vaccines Male age 18-50 years old
Exclusion criteria
* Adults unable to consent * Men who have been receiving Testosterone replacement therapy or anabolic steroids within the last year * Men with a history of male infertility * Men with a genetic or other medical condition known to be associated with decreased semen parameters Positive COVID-19 PCR test within the 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sperm density count/ml | up to 6 months | As measured from semen samples |
| Total sperm count per ejaculate | up to 6 months | As measured from semen samples |
| Percentage of motile sperm | up to 6 months | As measured from semen samples |
| Percentage of abnormal sperm forms | up to 6 months | As measured from semen samples |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Morning serum testosterone | up to 6 months | Total serum testosterone measured using immunoassay |
Countries
Egypt
Contacts
Primary ContactMohamed Tarek H Anis, M.D.
Backup ContactIslam Fathy, M.D.
Outcome results
None listed